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Abstract The clinical use of aminoglycoside (AG) anti-
biotics is limited by their renal toxicity, which is caused by
drug accumulation in proximal tubule (PT) cells. Clinical
studies reported that renal clearance of AG is enhanced in
cystic fibrosis (CF) patients, which might reflect the role of
CFTR in PT cell endocytosis. In order to assess the role of
chloride transporters on the renal handling of AG, we
investigated gentamicin uptake and renal accumulation in
mice lacking functional CFTR (CftrΔF/ΔF) or knock-out for
the Cl−/H+ exchanger ClC-5 (Clcn5Y/−). The latter represent
a paradigm of PT dysfunction and defective receptor-
mediated endocytosis. As compared with controls, CftrΔF/
ΔF and Clcn5Y/− mice showed a 15% to 85% decrease in
gentamicin accumulation in the kidney, respectively, in
absence of renal failure. Studies on primary cultures of
CftrΔF/ΔF and Clcn5Y/− mouse PT cells confirmed the
reduction in gentamicin uptake, although colocalization
with endosomes and lysosomes was maintained. Quantifi-
cation of endocytosis in PT cells revealed that gentamicin,
similar to albumin, preferentially binds to megalin. The
functional loss of ClC-5 or CFTR was reflected by a
decrease of the endocytic uptake of gentamicin, with a
more pronounced effect in cells lacking ClC-5. These
results support the concept that CFTR, as well as ClC-5,
plays a relevant role in PT cell endocytosis. They also
demonstrate that the functional loss of these two chloride
transporters is associated with impaired uptake of AG in PT
cells, reflected by a decreased renal accumulation of the
drug.
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Introduction
Aminoglycosides (AG) are among the most commonly
used antibiotics worldwide. Their activity against a wide
range of Gram-negative bacteria combined with a low rate
of reversible resistance makes AG the drug of choice to
treat life-threatening infections. However, nephrotoxicity of
AG, which is observed in up to 25% of treated patients,
represents a serious adverse event and is a dose-limiting
factor for their therapeutic use [1, 18]. AG are commonly
used to treat exacerbations of pulmonary infections (particu-
larly with Pseudomonas aeruginosa) in patients with cystic
fibrosis (CF). Nephrotoxicity of AG is particularly burden-
some in such patients, considering the tenacity of infections
and the necessity for repeated treatment courses [25]. A
further aspect is that CF patients show enhanced renal
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clearance for many drugs including AG [13, 30]. The
molecular basis of such enhanced drug clearance in CF—
increase in filtration, decrease in tubular reabsorption or
increase in tubular secretion—is debated and is probably
drug-specific [24].
Aminoglycosides are non-protein-bound drugs charac-
terized by low tissue penetrance and free glomerular
filtration. Around 80% of the administered dose is excreted
into the urine within 24 h. However, up to 5% of the dose is
reabsorbed in the proximal tubule (PT), where the drug
accumulates for a long time (half-life >100 h), leading to
renal damage [23, 33]. Aminoglycoside-induced kidney
failure is typically non-oliguric, with evidence of PT
dysfunction (renal Fanconi syndrome) and occasional
toxicity in more distal tubular segments, as reflected by
NaCl or magnesium wasting. However, accumulation
within the renal cortex, especially in PT cells, is thought
to play a key role in the pathogenesis of AG nephrotoxicity
[14].
Experiments in rat models have revealed that accumula-
tion of AG in PT cells is mediated by the multi-ligand
receptor, megalin [17]. Megalin and its co-receptor cubilin
are abundantly expressed at the apical surface of PT cells,
where they mediate the main endocytic pathway for
clearance of low-molecular-weight (LMW) proteins that
are ultrafiltered by the glomerulus [4]. Rare human
disorders caused by loss-of-function mutations in the genes
coding for megalin or cubilin, as well as animal models
with invalidated megalin or cubilin receptors, are invariably
associated with urinary loss of LMW ligands [6]. Apart
from these receptors, recent studies have revealed that
intravesicular chloride transporters may also play an
important role in the reabsorption of ultrafiltered ligands
[12]. In particular, the vesicular Cl−/H+ exchanger, ClC-5,
is crucial for receptor-mediated endocytosis and megalin/
cubilin trafficking in PT cells [5, 20, 32]. Mutations of the
CLCN5 gene that encodes ClC-5 cause Dent’s disease
(OMIM #30009), a rare X-linked renal tubulopathy
characterized by a generalized dysfunction of the PT
associated with LMW proteinuria [8]. More recently, Jouret
et al. have demonstrated that loss-of-function mutations in
the CF transmembrane conductance regulator (CFTR,
ABCC7) gene induce a moderate but significant PT
alteration of LMW protein handling [11]. Indeed, in mouse
kidney, CFTR co-distributes with ClC-5 and the vacuolar-
ATPase in endosomes located in the apical area of PT cells.
Furthermore, lack of CFTR in renal PT cells induces
instability of cubilin at the brush border, leading to its
accelerated shedding into urine and LMW proteinuria in
CF mice and patients [11]. Accordingly, a reduced
uptake of AG by PT cells could provide a mechanistic
explanation for the enhanced renal clearance of AG
observed in CF.
In order to test this hypothesis and investigate kidney
handling of AG, we performed in vivo and in vitro studies
to characterize gentamicin handling by PT cells. We used
two clinically relevant animal models, i.e. mice lacking
functional CFTR (CftrΔF/ΔF) and those knock-out for ClC-5
(Clcn5Y/−), a well-established model for Dent’s disease and
defective PT cell endocytosis.
Materials and methods
Mouse models
Experiments were conducted on age-matched and gender-
matched Cftr+/+ and mutated CftrΔF/ΔF mice (FVB/129
background) [31], and Clcn5Y/+ and Clcn5Y/− mice
(C57BL6 background) [32]. All mice had free access to
appropriate standard diet (Carfil Quality, Oud-Turnhout,
Belgium). The tap water of the Cftr mice was enriched with
Movicol (55.2 g/L; Norgine, Heverlee, Belgium). The
experiments were conducted in accordance with the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals and were approved by the Ethics
Committee of the Université catholique de Louvain.
Renal function and gentamicin handling
Mice were injected with a therapeutic dose (5 mg/kg body
weight) of gentamicin (Schering-Plough, Brussels,
Belgium) [9]. Blood was obtained by retro-orbital puncture
after 30 min, under anesthesia with Anesketin (Eurovet,
Brussels, Belgium) and Rompun (Bayer, Brussels,
Belgium). Subsequently mice were kept in metabolic cages
for 24 h with ad libitum access to food and drinking water.
Urine was collected, and blood was obtained by puncture of
the vena cava at the time of killing. Plasma and urine
concentrations of gentamicin were determined using an
AxSYM System (detection limit: 0.2 μg/mL; Abbott
Laboratories, Abbott Park, IL, USA). Plasma gentamicin
concentration at the time of sacrifice was undetectable, and
therefore only the peak concentration at 30-min post-
injection was assessed. Biological parameters in plasma
and urine were measured with a Synchron CX5 analyzer
(Beckman Coulter, Fullerton, CA), whereas Clara Cell
protein (CC16) concentration, a 16-kD marker of PT
dysfunction, was determined in duplicate by latex immu-
noassay [32].
A kidney was split in two parts; half was fixed for 6 h at 4°
C in 4% 0.1 M phosphate buffered (pH 7.4) formaldehyde
(Boehringer Ingelheim, Heidelberg, Germany), and the other
half was flash-frozen and stored at −80°C. The contralateral
kidney was homogenized in 0.25 M sucrose and 3 mM
imidazole buffer (pH 7.4) that contained Complete (Roche), in
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a Potter-Elvehjem tissue homogenizer (Thomas Scientific,
Swedsboro, NJ) [11]. The homogenate was centrifuged at
1000× g for 15 min at 4°C, and the supernatant was analyzed
biochemically for gentamicin concentration using the
AxSYM System. To confirm the early accumulation of
gentamicin in PT cells, some mice were sacrificed 10 min
after injection of gentamicin (5 mg/kg body weight), with
fixation of kidney samples as described previously.
Primary cell culture
Primary mouse proximal tubule cells (mPTC) were cultured
under sterile conditions from collagenase-digested cortical
fragments of kidneys isolated from male Clcn5 and Cftr
mice as previously described [27, 29]. Seven-day-old
confluent monolayers, which retain their differentiation
and endocytic capacity [21], were used for experiments.
Immunostaining
Kidney samples and mPTC were fixed in 4% formaldehyde
before embedding in paraffin as described [11]. After
incubation with 10% serum, kidney sections or mPTC
were incubated with primary antibodies diluted in
phosphate-buffered saline (PBS) containing 2% bovine
serum albumin (BSA). After washing, sections were
incubated with biotinylated secondary anti-IgG antibodies
(Vector Laboratories, Brussels, Belgium). Sections were
viewed under a Leica DMR coupled to a Leica DC300
digital camera (Leica, Heerbrug, Switzerland). For immu-
nofluorescence, Alexa-conjugated secondary anti-IgG anti-
bodies were used (Invitrogen, Merelbeke, Belgium). Nuclei
were stained with DraQ5™ (Biostatus, UK). Filters cut
from the holder or kidney sections were mounted in
Prolong Gold Anti-fade reagent (Invitrogen, Belgium).
Sections were analyzed under a Zeiss LSM510Meta
Confocal microscope (Zeiss, Belgium).
Antibodies
Immunostaining analyses were performed using well-
characterized rabbit monoclonal antibody against gentami-
cin (a gift from K. Fujiwara, Sojo University, Japan) [10],
mouse monoclonal antibody against early endosomal
antigen-1 (EEA1), and polyclonal antibodies against megalin
(a gift from P. Verroust, INSERM, Paris, France).
Gentamicin endocytosis
Characterization of the gentamicin uptake was performed in
fixed and live mPTC. Confluent monolayers of mPTC,
isolated from Clcn5 and Cftr mice, were exposed to
5 mg/mL gentamicin for 7 or 45 min at 37°C, fixed in
4% formaldehyde (see “Immunostaining”) and subsequent-
ly stained using anti-EEA1 and anti-gentamicin antibodies.
For live-cell imaging, confluent monolayers of mPTC were
simultaneously incubated with 1 mg/mL Alexa 488-
gentamicin and Lysotracker Red (Invitrogen, Merelbeke,
Belgium) for 7 min at 37°C and washed. Fluorescence was
chased up to 45 min after exposure of the cells to
gentamicin. Cells were examined using the Zeiss
LSM510Meta confocal microscope.
Quantification of endocytosis was performed as previ-
ously described [21]. Confluent mPTC were incubated with
Alexa488-conjugated gentamicin or Alexa488-conjugated
BSA (both at 0.5 mg/mL) for 15 min at 37°C. After
incubation, mPTC were washed five times with cold HBSS
(4°C) and lysed. The fluorescence in the lysate was
measured in a fluorimeter (Perkin Elmer) with excitation
at 490±10 nm and emission at 525±10 nm. For metabolic
inhibition experiments, mPTC were incubated with 10 mM
sodium azide or 50 mM 2-deoxyglucose (DOG) for 30 min
at 37°C before the endocytic assay. For competition
experiments, mPTC were simultaneously incubated with
50 mM unlabelled albumin or transferrin. Fluorescence was
normalized for the amount of protein in the cells, measured
using the BCA kit (Pierce, Belgium).
Data are expressed as mean±SEM. Significance of
differences was assessed by unpaired, two-tailed Student’s
t test.
Results
Renal function and gentamicin handling in Cftr and Clcn5
mice
We first investigated renal function and gentamicin concen-
trations in CftrΔF/ΔF and Clcn5Y/− mice in comparison with
their control littermates. Renal function as measured by
creatinine clearance, BUN and plasma creatinine levels was
similar for CFTR and ClC-5 mice as compared with wild-
type controls (Table 1). The CftrΔF/ΔF mice showed a
significant increase in the urinary albumin excretion as well
as LMW proteinuria as evidenced by the increased urinary
excretion of CC16. The Clcn5Y/− mice also presented with
albuminuria and LMW proteinuria, in a greater extent than
that observed in CftrΔF/ΔF mice. The Clcn5 knock-out mice
also showed polyuria (Table 1).
As for gentamicin handling, the peak plasma concentra-
tion of gentamicin was similar in wild-type and CftrΔF/ΔF
and Clcn5Y/− mice, indicating that the mice received a
similar dose of the drug (Table 2). In contrast, the
gentamicin concentration in the kidney 24 h after injection
was significantly lower in CftrΔF/ΔF mice (∼15% decrease)
and in Clcn5Y/− mice (∼85% decrease) (Table 2). These
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results show that, in absence of renal failure, renal
accumulation of gentamicin is significantly decreased in
mouse models of CF and Dent’s disease in parallel with the
degree of PT dysfunction in these models.
Immunolocalization of gentamicin and megalin in Cftr and
Clcn5 kidneys
To substantiate the handling data, we performed immunos-
taining for gentamicin (Fig. 1a) on kidney sections taken
from Cftr and Clcn5 mice 24 h post-injection. Gentamicin
was clearly detectable in PT sections of both Cftr+/+ and
Clcn5Y/+ kidneys, contrasting with decreased immunoreac-
tivity in CftrΔF/ΔF and Clcn5Y/− kidneys. A residual, faint
signal for gentamicin could be observed in PT profiles from
the CftrΔF/ΔF while no residual signal was detected in
Clcn5Y/− mice. Since gentamicin preferentially binds to
megalin, we investigated the immunoreactivity for megalin
in these very kidney sections from Cftr and Clcn5 mice
(Fig. 1b). In comparison with wild-type kidneys, only a
faint signal for megalin could be observed at the apical
region of PT in Clcn5Y/− kidneys, whereas megalin
expression was slightly reduced in CftrΔF/ΔF kidneys.
Immunofluorescence performed shortly (10 min) after
injection confirmed the gentamicin uptake in the apical
region of PT from Cftr+/+ kidneys, with an attenuated
immunoreactivity in CftrΔF/ΔF PT profiles (Fig. 1c). These
in vivo data suggest that the decreased renal accumulation
of gentamicin could result from a decreased receptor-
mediated uptake in PT cells.
Uptake of gentamicin in mPTC from Clcn5 and Cftr mice
We used a well-characterized mPTC culture system [29] to
evaluate the subcellular handling of gentamicin and its
dependence on CFTR and ClC-5 in PT cells. Primary
cultures of mPTC obtained from wild-type (Fig. 2a–d),
Clcn5Y/− (Fig. 2e–h), and CftrΔF/ΔF (Fig. 2i–l) mice were
exposed to gentamicin at 37°C for 7 min (early endocytosis)
and 45 min (late endocytosis and lysosomal processing). In
comparison with wild-type mPTC (Fig. 2a, b), the gentami-
cin uptake after 7 min was strongly reduced in Clcn5Y/− cells
(Fig. 2e, f), while a milder reduction was observed in CftrΔF/
ΔF mPTC (Fig. 2i, j). At 45 min, numerous large gentamicin-
positive vesicles could be observed in wild-type mPTC
(Fig. 2c, d). A smaller number of positive vesicles were
detected in Clcn5Y/− (Fig. 2g, h) and CftrΔF/ΔF (Fig. 2k, l)
mPTC.
We next used mPTC to identify the localization of
gentamicin within the endosomal–lysosomal pathway.
Monolayers of mPTC were double stained for gentamicin
and anti-early endosomal antigen-1 (EEA1) after incubation
with gentamicin for 7 min (Fig. 3). In wild-type mPTC,
gentamicin colocalized with EEA1, confirming its presence
in the early endosomes (Fig. 3a–c). By contrast, almost no
gentamicin could be detected in Clcn5Y/− mPTC (Fig. 3d),
whereas a markedly reduced staining was detected in
Table 1 Clinical and biochemical parameters in Cftr and Clcn5 mice
Cftr+/+ CftrΔF/ΔF ClCn5Y/+ Clcn5Y/−
Body weight (g) 26.2±1.3 25.2±0.9 24.6±0.4 29.1±0.4b
BUN (mg/dL) 25±0.5 27±3.3 27±2.8 25±1.7
Plasma creatinine (mg/dL) 0.072±0.02 0.076±0.02 0.086±0.02 0.08±0.01
Diuresis (μL/24 h) 708±87 704±123 996±176 2317±447b
Creatinine clearance (μL/min·g BW) 37±10 40±7 17±4 23±3
Urinary albumin (μg/g creat) 1893±1385 10,869±3513a 798±761 58,608±3041c
Urinary CC16 (μg/g creat) 42±23 132±20a 1.7±0.9 37,665±10,877d
There were 5 pairs of age-matched and gender-matched mice per genotype
BUN blood urea nitrogen, creat creatinine
a p<0.05 vs. Cftr+/+
b p<0.05 vs. Clcn5Y/+
c p<0.0001 vs. Clcn5Y/+
d p<0.01 vs. Clcn5Y/+
Table 2 Gentamicin handling by Cftr and Clcn5 mice
Cftr+/+ CftrΔF/ΔF ClCn5Y/+ Clcn5Y/−
Plasma gentamicin
(μg/mL)
7.2±0.5 7.9±1.2 6.7±0.6 8.8±0.7
Kidney gentamicin
(μg/mL)
0.89±0.1 0.75±0.1a 0.66±0.1 0.1±0.05b
Plasma gentamicin is peak values obtained at 30 min post-injection;
kidney gentamicin is measured at 24 h post-injection. There were 5
pairs of age-matched and gender-matched mice per genotype
a p<0.05 vs. Cftr+/+
b p<0.0001 vs. Clcn5Y/+
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CftrΔF/ΔF mPTC (Fig. 3g). The few vesicles that contained
gentamicin stained positive for EEA1, indicating the
involvement of early endosomes (Fig. 3i).
A pulse-chase experiment was performed to investigate
the progression of gentamicin into the lysosomal compart-
ment of mPTC (Fig. 4). Monolayers of wild-type (Fig. 4a–
c), Clcn5Y/− (Fig. 4d–f), and CftrΔF/ΔF mPTC (Fig. 4g–i)
were exposed to Alexa 488-gentamicin and Lyso Tracker
Red, and gentamicin localization was analyzed after
45 min. In wild-type mPTC, gentamicin colocalized with
LysoTracker Red (Fig. 4c) confirming intra-lysosomal
capture. A reduction of gentamicin uptake was detected in
Clcn5Y/− and CftrΔF/ΔF mPTC (Fig. 4d, g, respectively),
with occasional colocalization of few gentamicin-positive
Clcn5Y/+ Clcn5Y/-
PT
G
PT
a
b
PT
PT PT
PT
Cftr+/+ Cftr F F
G
G
PT PT
PT
G
PT
PT
PT
Clcn5Y/+ Clcn5Y/-
Cftr+/+ Cftr F F
Fig. 1 Gentamicin uptake and
megalin expression in Cftr and
Clcn5 kidneys. a Immunostain-
ing for gentamicin in Cftr and
Clcn5 kidneys 24 h post-
injection of gentamicin
(5 mg/kg) showing segmental
gentamicin staining in the
proximal tubules (PT) of both
wild-type Cftr+/+ and Clcn5Y/+
kidneys. In contrast, the staining
is abolished in the proximal
tubules of Clcn5Y/− kidneys and
is weakly detected in CftrΔF/ΔF
kidneys. b Immunostaining for
megalin showing a strong ex-
pression at the apical region of
the cells lining the proximal
tubules in the wild-type Cftr+/+
and Clcn5Y/+ kidneys. In
contrast, the staining is almost
undetectable in Clcn5Y/−
kidneys and is slightly decreased
in CftrΔF/ΔF kidneys. Scale bar:
50 μm (a), 100 μm (b). c
Immunofluorescent staining for
gentamicin in Cftr kidneys
10 min post-injection. Positive
signal for gentamicin is
observed in the subapical area of
the cells lining proximal tubules
(PT) of Cftr+/+ kidneys. The
signal is attenuated in the
proximal tubules of CftrΔF/ΔF
kidneys. Scale bar: 50 μm (a),
100 μm (b and c)
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vesicles with the lysosomal marker (Fig. 4f, i). Taken
together, these data demonstrate that uptake of gentamicin
and its progression along the endosomal–lysosomal path-
way are affected by the functional loss of CFTR or ClC-5 in
PT cells.
Quantification of gentamicin endocytosis in mPTC
from Clcn5 and Cftr mice
To monitor the effect of CFTR or ClC-5 loss on gentamicin
uptake, we incubated mPTC from ClCn5 and Cftr mice for
Cftr F FCftr +/+
G
G
c
Fig. 1 continued.
CA B D
Wild-type
GE HF
Clcn5Y/-
LKJI
Cftr F F
nim54nim7
Fig. 2 Gentamicin uptake in proximal tubule cells. Primary cultures
of proximal tubule cells (mPTC) obtained from Clcn5Y/+ (wild-type,
a–d), Clcn5Y/− (e–h), and CftrΔF/ΔF (i–l) kidneys exposed to 5 mg/mL
gentamicin (37°C for 7 min or 45 min). Staining with anti-gentamicin
and labeling with Alexa488 IgG were analyzed by confocal
microscopy. Nuclei counterstained with DraQ5™ (red). In comparison
with wild-type mPTC (a–b), Clcn5Y/− cells showed a drastically
reduced early (7 min) uptake of gentamicin (e–f), while a milder
reduction was observed in CftrΔF/ΔF mPTC (i–j). At 45 min,
numerous large gentamicin-positive vesicles could be observed in
wild-type mPTC (c–d). A smaller number of positive vesicles were
detected in Clcn5Y/− (g–h) and CftrΔF/ΔF (k–l) mPTC. No difference
in staining could be observed between mPTC obtained from wild-type
Clcn5Y/+ and Cftr+/+ kidneys, and therefore a representative image of
wild-type mPTC is shown. Scale bar: 10 μm
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CBA
Wild-type
FED
Clcn5Y/-
IG H
Gentamycin EEA1 Merge
Cftr F F
Fig. 3 Early localization of
gentamicin in endosomes.
Primary cultures of Clcn5Y/+
(wild-type, a–c), Clcn5Y/− (d–f),
and CftrΔF/ΔF (g–i) mPTC
exposed to 5 mg/mL gentamicin
(7 min at 37°C), fixed and
stained with anti-gentamicin
(Alexa488; a, d, g) and
anti-EEA1 (Alexa568; b, e, h).
Nuclei counterstained with
DraQ5™ (blue). Gentamicin
colocalizes with EEA1 in
multiple vesicles in control
mPTC, contrasting with a lower
density of vesicles observed in
the Clcn5Y/− and CftrΔF/ΔF cells
(Merge panels, yellow spots).
Scale bar: 10 μm
CBA
Wild-type
FED
-Clcn5Y/
IHG
G t i L t k R den amyc n yso rac er e Merge
Cftr F F
Fig. 4 Late localization of
gentamicin in lysosomes.
Primary cultures of Clcn5Y/+
(wild-type, a–c), Clcn5Y/− (d–f),
and CftrΔF/ΔF (g–i) mPTC
exposed to 1 mg/mL Alexa488-
gentamicin (green; a, d, g) and
LysoTracker Red (red; b, e, h)
for 7 min at 37°C and followed
up for 45 min using live-cell
imaging. Gentamicin colocalizes
with LysoTracker after 45 min
(yellow spots, merge panels), but
a much lower density of positive
vesicles was observed in
Clcn5Y/− and CftrΔF/ΔF cells.
Scale bar: 5 μm
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15 min with similar, non-toxic concentrations of Alexa488-
gentamicin or Alexa488-BSA, taken as a well-established
ligand for megalin. The uptake of gentamicin or albumin
was then analyzed (i) under control conditions, (ii) in the
presence of competitive inhibitors of megalin (excess of
albumin) or cubilin (excess of transferrin), and (iii) in
conditions of metabolic inhibition (Fig. 5). In control
mPTC, the amount of accumulated gentamicin was similar
to that of albumin (70±4 vs. 71±2 ng/μg protein
respectively). Competitive or metabolic inhibition could
block gentamicin and albumin uptake by mPTC. As
compared to wild-type mPTC, gentamicin and albumin
uptake was reduced by ∼75% in Clcn5Y/− mPTC and
by ∼20% in CftrΔF/ΔF mPTC. These results show that
functional loss of ClC-5 or CFTR is reflected by a
significant loss in the endocytic uptake of gentamicin
(and albumin) by PT cells; this effect is much more
pronounced in cells lacking ClC-5 than in those lacking
CFTR.
Discussion
In this study, we analyzed the handling of AG by PT cells
using in vivo and in vitro experiments performed on CftrΔF/ΔF
and Clcn5Y/− mice. Both strains showed a decreased
accumulation of gentamicin in the kidney, despite similar
levels of renal function and peak gentamicin concentration in
the blood. A reduction in the renal uptake of gentamicin was
confirmed in mPTC obtained from CftrΔF/ΔF and Clcn5Y/−
mice, with much fewer gentamicin-positive vesicles in the
early endosomal and lysosomal compartments. The reduction
in endocytic uptake was much more pronounced in cells
lacking ClC-5 than in those lacking CFTR. These results
confirm the role of CFTR in PT cell endocytosis and
demonstrate that the functional loss of CFTR, as that of
ClC-5, is associated with a decreased efficacy of receptor-
mediated uptake in PT cells, causing a decreased renal
accumulation of AG.
Among other factors, aggressive antibiotic treatment for
lung infections has led to a dramatic increase in life
expectancy for patients with CF over the last three decades
[25]. Because of their efficacy against P. aeruginosa, AG
antibiotics are particularly useful to treat chronic lung
infections in CF patients [2, 22]. In the general population,
up to 25% of treated patients will present AG-induced
nephrotoxicity, despite accurate follow-up [14]. The renal
toxicity of AG is clearly related to their uptake along the PT
segments via receptor-mediated endocytosis [23], accumu-
lation in endo-lysosomal vesicles, modification of the
membrane phospholipid content, leakage in the cytosol,
and subsequent toxicity for mitochondria and endoplasmic
reticulum, activating different pathways leading to cell
death [14, 24]. It is known for a long time that CF patients
display an enhanced renal clearance for several drugs
including AG [13, 26, 30]. Since protein binding is
generally unchanged in CF patients and no significant
differences in glomerular filtration rate have been found in
most studies [26, 30], a possible role for defective
endocytic uptake has been evoked. This hypothesis has
first been substantiated by Jouret et al., who evidenced a
defect in receptor-mediated endocytosis in CF mouse
models and CF patients [11]. These studies revealed that
CFTR, like ClC-5, is expressed in the endosomes of PT
cells [7]. Mice knock-out for CFTR or harboring the
F508del mutation presented with a mild but significant
albuminuria and LMW-proteinuria, caused by a defective
receptor-mediated endocytosis. Patients with CF showed a
similar defect in LMW protein handling [11].
To investigate the putative link between defective
endocytosis and changes in gentamicin handling in CF, we
compared the CftrΔF/ΔF mouse vs. the Clcn5Y/− mouse
model of Dent’s disease. The CftrΔF/ΔF mouse model bears
the most common mutation in CF (F508del) [31], which
results in misfolding and lack of maturation of CFTR that
cannot reach the apical plasma membrane. Instead, the
mutated protein does not escape the endoplasmic reticulum
quality control and is degraded by the ubiquitin–proteaso-
mal pathway [3]. However, the CftrΔF/ΔF tissues show a
80
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Wt mPTC
Clcn5Y/-
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Fig. 5 Quantification of gentamicin uptake in mPTC. Primary
cultures of wild-type (Wt) mPTC (open bars), Clcn5Y/− (striped
bars), and CftrΔF/ΔF (dashed bars) mPTC exposed to 0.5 mg/mL
Alexa488-gentamicin (white bars) or 0.5 mg/mL Alexa488-BSA (grey
bars) for 15 min at 37°C under control conditions or in the presence of
excessive amount of competitive inhibitors albumin (+Alb) or
transferrin (+Tf) or after metabolic inhibition (MI). The uptake of
albumin and gentamicin is decreased in a variable extent in the
Clcn5Y/− vs. the CftrΔF/ΔF mPTC. The residual uptake after compet-
itive inhibition with an excess of ligands or with metabolic inhibition
is shown for comparison. Data are mean±SEM of 6 experiments
(n=6). Statistical differences are indicated with *p<0.001 and
**p<0.01 vs. Wt mPTC
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residual Cl− conductance, suggesting that the mutant
F508del-CFTR is partially processed and reaches the
plasma membrane in several tissues including the kidney
[19, 31]. This residual activity may explain, at least
partially, the less severe PT phenotype in the CftrΔF/ΔF
mouse as compared with the Clcn5Y/− mouse which
displays a severe trafficking defect of megalin and cubilin
resulting in a massive endocytic defect and generalized PT
dysfunction [5, 20, 32]. Our data confirm the quantitative
difference in LMW proteinuria and extend it to the renal
handling of gentamicin. The decreased renal accumulation
of gentamicin in both models could result from a decreased
reabsorption as evidenced by immunostaining and quanti-
tative AG analyses in kidney extracts.
Previous studies have identified receptor-mediated
endocytosis through binding of megalin as the primary
route of uptake for polybasic drugs such as AG [15, 16, 23,
28]. Our in vivo studies show a mild (CftrΔF/ΔF) or
dramatic (Clcn5Y/−) reduction in megalin staining in PT
segments, which could explain the enhanced gentamicin
clearance and the decreased renal accumulation. For a more
comprehensive investigation of gentamicin handling by PT
cells, we used primary cultures of mPTC which remain well
differentiated and keep essential properties such as
receptor-mediated endocytosis [29]. For instance, we
recently showed that the endocytic defect of Clcn5Y/− mice
was retained in primary cultured mPTC [21] and that these
cells were responding to a transcriptional program of
differentiation [27]. Using this system, we demonstrated
that the lack of functional CFTR leads to a significant
∼20% decrease in gentamicin and albumin uptake, as
compared with a major ∼80% reduction in cells KO for
ClC-5. The fact that similar proportions were obtained for
gentamicin clearance and kidney accumulation highlights
the correspondence between the distinct methodological
approaches targeting the endocytic defect in vivo and in
vitro. The sensitivity of gentamicin uptake to metabolic and
competitive inhibition (with both excess of albumin and
transferrin) identified the energy-demanding receptor-
mediated endocytosis pathway using the multiligand recep-
tors megalin and cubilin as the primary uptake route for
gentamicin in mPTC.
Our investigation focusing on the trafficking of genta-
micin by colocalization with endosomal and lysosomal
markers confirmed the AG processing in PT cells. In wild-
type mPTC, gentamicin colocalized with EEA1 in the early
endosomal pathway after 7-min incubation, whereas most
of the gentamicin was localized in lysosomes after 45 min.
The gentamicin uptake was reduced in CftrΔF/ΔF and
Clcn5Y/− mPTC, but rare colocalization with endosomal
and lysosomal markers could be observed. The fact that
gentamicin is taken up by receptor-mediated endocytosis
and routed to lysosomes opens possibilities to prevent drug
accumulation in the PT and thus limiting nephrotoxicity.
The search for strategies to prevent the binding of
gentamicin to megalin has been initiated [14, 16]. Finally,
the different handling of gentamicin observed in the mouse
models tested here may suggest that dosage adaptation and
drug monitoring is particularly important when using AG in
patients suffering from a defective endocytosis and LMW-
proteinuria, including CF and Dent’s disease.
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